US EditionSoleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech With A 35.95% Potential Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech With A 35.95% Potential Upside
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is capturing the attention of investors with its promising potential upside of 35.95%. As a clinical-stage biopharmaceutical company based in Redwood City, California, Soleno is focused on developing novel therapeutics for treating rare diseases. Its lead product candidate, Diazoxide Choline Extended-Release tablets, is currently in Phase III clinical trials for Prader-Willi Syndrome, a rare genetic disor…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
